Selection of DNA nanoparticles with preferential binding to aggregated protein target. by Ruff, Laura E et al.
UC San Diego
UC San Diego Previously Published Works
Title
Selection of DNA nanoparticles with preferential binding to aggregated protein target.
Permalink
https://escholarship.org/uc/item/6327j29b
Journal
Nucleic acids research, 44(10)
ISSN
0305-1048
Authors
Ruff, Laura E
Sapre, Ajay A
Plaut, Justin S
et al.
Publication Date
2016-06-01
DOI
10.1093/nar/gkw136
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Published online 11 March 2016 Nucleic Acids Research, 2016, Vol. 44, No. 10 e96
doi: 10.1093/nar/gkw136
Selection of DNA nanoparticles with preferential
binding to aggregated protein target
Laura E. Ruff1,*, Ajay A. Sapre2, Justin S. Plaut2, Elisabeth De Maere3, Charlotte Mortier3,
Valerie Nguyen1, Kevin Separa1, Sofie Vandenbogaerde3, Laura Vandewalle3, Sadik
C. Esener4 and Bradley T. Messmer1,*
1UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA, 2Department of
Bioengineering, University of California San Diego, La Jolla, CA 92093, USA, 3Department Vesalius, Hogeschool
Ghent, Ghent 9000, Belgium and 4Department of Nanoengineering, University of California San Diego, La Jolla, CA
92093, USA
Received November 23, 2015; Revised February 22, 2016; Accepted February 24, 2016
ABSTRACT
High affinity and specificity are considered essential
for affinity reagents and molecularly-targeted ther-
apeutics, such as monoclonal antibodies. However,
life’s own molecular and cellular machinery consists
of lower affinity, highly multivalent interactions that
are metastable, but easily reversible or displaceable.
With this inspiration, we have developed a DNA-
based reagent platform that uses massive avidity
to achieve stable, but reversible specific recognition
of polyvalent targets. We have previously selected
these DNA reagents, termed DeNAno, against vari-
ous cells and now we demonstrate that DeNAno spe-
cific for protein targets can also be selected. DeNAno
were selected against streptavidin-, rituximab- and
bevacizumab-coated beads. Binding was stable for
weeks and unaffected by the presence of soluble tar-
get proteins, yet readily competed by natural or syn-
thetic ligands of the target proteins. Thus DeNAno
particles are a novel biomolecular recognition agent
whose orthogonal use of avidity over affinity results
in uniquely stable yet reversible binding interactions.
INTRODUCTION
DeNAno DNA particles are a novel multivalent reagent
that relies on high overall avidity instead of high affinity to
bind their targets. DeNAno particles that specifically bind
to primary human dendritic cells (1) and the mouse pan-
creatic cancer cell line Panc-02 (2) have been selected pre-
viously. The selection process is a biopanning strategy akin
to that used in aptamer selection by systemic evolution of
ligands by exponential enrichment (SELEX), in which a
highly diverse library of DNA particles is incubated with
the target to capture binders followed by amplification and
iteration of the process. While aptamers are generally small
pieces of DNA or RNA (<100 bp) that bind in a monova-
lent fashion with high affinity, DeNAno are concatemers of
up to several hundred copies in lengthmade by rolling circle
amplification (RCA), with sizes that can be several hundred
nanometers (2). This long strand of DNA forms secondary
and tertiary structure, which is the basis for ability to bind
their targets specifically. In general, folding of ssDNA is de-
pendent on conditions such as temperature, buffer condi-
tions, base-pairing and electrostatic interactions. As with
aptamers, DeNAno selection does not require prior knowl-
edge of the target, thus selection on complex targets such
as cells is possible. Aptamers have been multimerized via
RCA (3), standard nucleic acid chemistry (4) or attach-
ment to nanoparticles (5,6). However, aptamers are––by
definition––high affinity, and particles selected in the mul-
tivalent format of DeNAno may bind in a different fashion
than these multimerized aptamers, leading to identification
of different types of binding molecules. Specifically, a De-
NAno particle may have many low, monovalent affinity in-
teractions that equal a high overall avidity or the DeNAno
may require a minimum copy number to produce the 3D
structure required for binding.
The selection process for aptamers and DeNAno is sim-
ilar. Briefly, in SELEX, a library of 1012–1015 oligonu-
cleotides (DNAorRNA) is incubated with a target, washed
or otherwise purified, and re-amplified via defined primer
sites at the 5′ and 3′ ends of the aptamer. The random region
of the aptamer is generally 60–80 bp in length. This pro-
cess is repeated until binding clones dominate the pool (7,8).
The selected aptamers are cloned, sequenced and analyzed,
and a binding motif is often identified. These aptamers can
have nM-pMaffinity, similar to an antibody. Aptamers have
been shown to bind via the 3D structure of their primary se-
quence through a combination of van der Waals forces, hy-
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drogen bonding, salt bridges, hydrophobic interactions and
electrostatic interactions (9,10). Selection of DeNAno par-
ticles occurs in a similar fashion. DeNAno are made via
RCA of circularized oligonucleotide templates containing
random regions of sequence. The resulting DeNAno is a
concatemer of single-strandedDNAwith sequence comple-
mentary to the circularized oligonucleotide template. 1010–
1011 particles are incubated with a target, washed and re-
amplified via defined primer sites at the 5′ and 3′ ends of the
oligonucleotide template. The template strand is enriched
via asymmetric polymerase chain reaction (PCR), circular-
ized and the selection process is repeated until binding par-
ticles dominate the pool. As with aptamers, DeNAno with
primary sequence motifs have been identified (2).
In this paper, DeNAno particles that bind to specific pro-
teins are identified and characterized. Streptavidin was used
as a well-characterized model system and monoclonal anti-
bodies were chosen to confirm these results because of their
potential use in biologic assays. Two intriguing phenomena
were observed during the course of this study: (i) DeNAno
were displaced from their target by the corresponding lig-
and and this event could be quantitated in multiple ways
and (ii) DeNAno preferentially bound aggregated rather
than free target. The findings described in this paper set
the stage for several novel applications of DeNAno affinity
reagents, such as ‘wash-free’ immunoassays and massively
parallel multiplexed assays.
MATERIALS AND METHODS
DeNAno particle synthesis and characterization
DeNAno particles were made by RCA, as previously de-
scribed (1). Briefly, a 100-bp template oligo (Integrated
DNA Technologies; IDT, Coralville, IA, USA, all oligos
from IDT unless otherwise specified) was circularized via a
40-bp complementary oligo and ligated with T4 ligase (New
EnglandBiolabs; NEB, Ipswich,MA,USA). RCAwas then
performed on this template, using the complementary oligo
as the initiating oligo and phi29 DNA polymerase (NEB).
RCAwas performed at 30◦C for 30m, with a dNTP concen-
tration of 3 nmol or 93.8 pmol. Enzymewas heat inactivated
at 65◦C for 10 m or 95◦C for 5 m. The resulting DeNAno
particles are concatemers complementary to the circular-
ized template. Their size is influenced by the amount of time
the reaction is run and the concentration of dNTPs (NEB).
For fluorescent readouts, particles were labeled with 1/10
molar ratio Alexa Fluor 647-labeled complementary oligo.
For streptavidin experiments, positive control particles were
made by labeling particles with 1/10 molar ratio 5′ biotiny-
lated complementary oligo (see Supplementary Table S1 for
oligo sequences).
Beads
Streptavidin-coated magnetic beads (NEB) were used
for selections/staining for streptavidin-specific DeNAno
with no modifications. For rituximab and bevacizumab
selections/staining, coated beads were made as follows:
6 m polystyrene beads (Polysciences, Warrington, PA,
USA) were washed with 20 mM sodium phosphate buffer
pH 7.5 (Boston BioProducts, Ashland, MA, USA), then
coated with 100 g/ml rituximab (Genentech, South San
Francisco, CA, USA), bevacizumab (Genentech), or poly-
clonal human IgG (Thermo Fisher Scientific, Waltham,
MA, USA) diluted in 20 mM sodium phosphate pH 7.5.
Beads and antibody were incubated for 2 h at room tem-
perature (RT) or overnight at 4◦C. Non-adsorbed antibody
was removed with 3 × 1 ml washes with 20 mM sodium
phosphate pH 7.5. Finally, beads were resuspended in phos-
phate bufferedsaline (PBS) (without calcium and magne-
sium, Mediatech, Manassas, VA, USA) supplemented with
0.02% NaN3 (Ricca Chemical Company, Arlington, TX,
USA).
In one control experiment, streptavidin polymethyl
methacrylate (PMMA) (Sapidyne Instruments, Boise, ID,
USA) and streptavidin sepharose (GE Healthcare Life Sci-
ences, Piscataway, NJ, USA) were used in place of strepta-
vidin magnetic beads.
DeNAno selections
DeNAno selections were performed as previously de-
scribed, with minor modifications (1). For the streptavidin
and rituximab selections, 3 × 1010 nanoparticles were incu-
bated with target beads for 20 m at RT. For streptavidin,
the target was streptavidin-coated magnetic beads; for rit-
uximab selections, the target was rituximab-coated beads
(described above). Non-binding particles were removed by
repeated washes. Bound DeNAno particles were amplified
by Hemo KlenTaq (NEB) back to the 100-bp oligo, and
the template strand was amplified by asymmetric PCR.
The template strand was then re-circularized as above and
the entire process repeated through 4–5 rounds of selec-
tion. 100-bp oligos were then cloned into pGEM T-easy
vector (Promega, Madison, WI, USA), transformed into
NEB 5-alpha high efficiency competent cells (NEB) and se-
quenced via colony PCR (Eton Bioscience Inc, San Diego,
CA, USA).
Selection on bevacizumab-coated beads differed in these
ways: round one selection was performed with 10 times
more particles (3 × 1011 unique particles) and selection was
performed overnight at 4◦C. Subsequent selection rounds
were performed for 2–4 h at RT, but with a standard num-
ber of DeNAno particles (3 × 1010). These conditions were
employed becausemultiple selection attempts with the stan-
dard conditions failed.
DeNAno staining
For initial experiments, clones of selected particles were
generated via PCR of the pGEM T-easy insert, followed
by asymmetric PCR to amplify the template strand. Circu-
larization and RCA were then performed, as above. RCA
conditions were 30◦C for 30 m with 3 nmol dNTP, followed
by heat inactivation for 10 m at 65◦C––these are the stan-
dard RCA conditions used, unless otherwise noted. Tem-
plates for clones of interest were synthesized (IDT).
All stainings were performed in a pre-blocked 96-well
v-bottom plate. Pre-block was PBS 1% bovine serum al-
bumin (BSA) (Sigma, St Louis, MO, USA) supplemented
with 10 mM MgCl2 (Teknova, Hollister, CA, USA; PBS
1% BSA 10 mM MgCl2). Unless otherwise noted, ∼3 ×
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1010 fluorescently-labeled particles were incubated with 2l
coated beads for 20 m at RT in PBS 10 mM MgCl2. Beads
were then washed once with PBS 10 mM MgCl2, twice by
Tris-buffered saline (Mediatech) 0.05% Tween-20 (Thermo
Fisher Scientific) 10 mM MgCl2 (TBST 10 mM MgCl2),
once with PBS 10 mM MgCl2 and resuspended in PBS
10 mM MgCl2. Washes were performed by magnetic pull-
down (streptavidin beads) or centrifugation at 1000 × g for
3 m (rituximab and bevacizumab beads). Fluorescence was
measured with a multimode microplate reader (TECAN,
Ma¨nnedorf, Switzerland).
Transmission electron microscopy
All transmission electron microscopy (TEM) Images were
taken on a FEI Technai G2 Sphera transmission electron
microscope (FEI, Hillsboro, OR, USA) operating at 200
kV. Copper grids (formvar/carbon-coated, 400 mesh cop-
per, Ted Pella, Inc., Redding, CA, USA) were prepared by
glow discharging the surface at 20 mA for 1.5 m followed
by treatment with 20 l 100 mMMgCl2 for 1 m in order to
prepare the surface for DNA nanoparticle adhesion. The
solution was wicked away and 4 l of DeNAno sample was
deposited on the grid and allowed to sit for 30 s. All grids
were treated with three drops of 1% w/w uranyl acetate
(Mallinckrodt, Dublin, Ireland) to provide negative stain-
ing. DeNAno particles were dialyzed into 10 mM Tris 10
mMMgCl2 pH8.5 prior to imaging and loading on the grid,
using a slide-a-lyzer 10KMWCO dialysis cassette (Thermo
Fisher Scientific).
Atomic force microscopy
Samples were prepared on freshly cleaved muscovite mica
(Ted Pella, Inc.). Mica disks were nicked with a scalpel and
vacuum cleaved then coated with a 0.005% w/v aqueous
solution of poly-L-lysine (PLL, MW 30–70 kDa, Sigma),
rinsed with deionized water, and dried overnight in a dessi-
cator. Dialyzed SA-D8 particles (prepared as in TEM) were
adsorbed to the PLL-mica for 30 m, rinsed with deionized
water and dried in a dessicator until imaged.
Images were acquired using ScanAsyst Si3N4 probes
(Al-coated, 0.4 N/m spring constant, Bruker, Billerica,
MA, USA) with PeakForce Tapping Mode on a Multi-
Mode 8 atomic force microscope (NanoScope VController,
Bruker).
dNTP dilution experiment
For dNTP dilution experiment, standard particles
were made––30 m/30◦C/3 nmol dNTP, as well as 30
m/30◦C/93.8 pmol dNTP. These particles were all heat
inactivated at 95◦C for 5 m. Control particles from another
library (V10control) with the same conditions were also
made and used as an internal control in the staining.
Unlabeled DeNAno particles were mixed with the internal
control particles of the same size/condition and incubated
with 8 g streptavidin beads for 2.5 h at RT in PBS 1% BSA
10 mM MgCl2. Samples were resuspended and an aliquot
was taken before proceeding to the wash step. Beads were
then washed via magnetic pulldown, once with PBS 1%
BSA 10 mM MgCl2, three times with TBST 1% BSA 10
mM MgCl2, once with PBS 1% BSA 10 mM MgCl2 and
resuspended in PBS 1% BSA 10 mM MgCl2. Bound and
total samples were analyzed by qPCR. A standard was run
for each library (a plasmid containing the 100bp template
used to make DeNAno). The ratio of the bound particles
(streptavidin DeNAno:control DeNano) to total particles
(streptavidin DeNAno:control DeNAno) is graphed.
Competitive titration experiment
For competitive titration experiments, biotin (Kd ∼10−15
M), d-desthiobiotin (Kd ∼10−11 M) or 2-iminobiotin (Kd
∼10−8 M at pH7.5; all from Sigma) were pre-incubated
with streptavidin beads for 20 m in DPBS (with calcium
and magnesium; Mediatech) 1% fetal bovine serum (FBS;
Omega Scientific, Tarzana, CA, USA) or rituximab-specific
peptide or irrelevant peptide were pre-incubated with ritux-
imab beads for 20 m in PBS 10 mMMgCl2. Fluorescently-
labeled particles were then added and allowed to incubate
for a further 20 m. Washes were performed via magnetic
pulldown for streptavidin beads or centrifugation at 1000
× g for 3 m for rituximab beads. A biotinylated particle was
used as a positive control for streptavidin experiment.
For streptavidin competitive titration experiment, free
streptavidin was pre-incubated with fluorescently-labeled
DeNAno for 20 m in DPBS 1% FBS, followed by addition
of streptavidin magnetic beads for a further 20 m. Washes
were performed via magnetic pulldown. A biotinylated par-
ticle was used as a positive control.
Competitive release experiment
For biotin and streptavidin competitive release experi-
ments, fluorescently-labeled particles were pre-incubated
with streptavidin beads in DPBS 1% FBS for 20 m at
RT. Biotin, d-desthiobiotin, 2-iminobiotin or streptavidin
(ProSpec, East Brunswich, NJ, USA) were then added and
incubated for an additional 20 m. Washes were performed
as above. A biotinylated particle was used as a positive con-
trol.
For rituximab/peptide competitive release experiments,
particles were pre-incubated with rituximab beads in PBS
10 mM MgCl2 for 20 m at RT. A total of 50 g/ml ritux-
imab peptide, irrelevant peptide or buffer were then added
and incubated for an additional 1 h. An aliquot of this total
sample was taken, then the beads were spun down at 1000
× g for 3 m and the supernatant was collected. The super-
natant was spun down an additional two times to ensure
that all beads were removed from the sample. DeNAno con-
tent of total and supernatant samples was thenmeasured by
qPCR, using a plasmid containing 100-bp oligo from the
same library as a standard. % release was measured as su-
pernatant DeNAno/total DeNAno * 100%.
DeNAno dissociation experiment
For dissociation experiment, standard conditions were used
to make DeNAno particles. Unlabeled DeNAno particles
were incubated with 8 g streptavidin beads for 2.5 h at
RT in PBS 1% BSA 10 mM MgCl2 and washed as in the
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dNTP dilution experiment. Samples were then resuspended
in 10 ml PBS 1% BSA 10 mM MgCl2 and stored at 4◦C.
At days 1, 8, 14, 21, 28 and 35 aliquots of total sample
(beads + supernatant) and supernatant-only were taken. To
acquire supernatant-only, 100 l of total sample was incu-
bated on a magnet for 5 m to remove beads from sample.
Supernatant was removed to a new well and the procedure
was repeated twice more. Total and dissociated samples
were analyzed by qPCR and quantitated with a standard
for that library. Percentage released DeNAno is graphed
(dissociated/total*100%).
Rituximab-binding peptide
Rituximab-binding peptide sequence and irrelevant pep-
tide sequence was ordered from (Genscript, Piscataway, NJ,
USA). The rituximab-binding peptide has been shown to
bind at the antigen-binding site of rituximab and compete
with target cell surface receptor for mAb binding. TheKd of
surface immobilized peptide-whole antibody was reported
to be 131 nMand 3.99Mfor surface immobilized peptide-
Fab fragment (11) Peptide was used in place of recombinant
CD20 due to the amount required for titration and release
experiments.
Protein G sandwich assay
For protein G sandwich assay, fluorescently-labeled
rituximab-specific, bevacizumab-specific or library nega-
tive DeNAno particles or anti-human kappa light chain
antibody (clone HP6062; Thermo Fisher Scientific) were
used. Protein G magnetic beads (Thermo Fisher Scientific)
were incubated with rituximab or bevacizumab for 1 h at
RT in PBS 1%BSA 10mMMgCl2. For anti-kappa samples
only: mouse IgG2b (clone eBM2b; eBioscience, San Diego,
CA, USA) was added to rituximab and bevacizumab
samples that would be less than saturating (<1-fold on
graph) to bind all the protein G so anti-kappa antibody
would not bind to these non-specifically. DeNAno particles
or anti-human kappa light chain antibody Alexa Fluor
488 (Thermo Fisher Scientific Inc) were then added and
incubated for 2 h at RT (no washing step was performed
prior to their addition). After incubation, all samples were
washed via centrifugation (900 × g, 3 m), once with PBS
1% BSA 10 mM MgCl2, three times with TBST 1% BSA
10 mM MgCl2, once with PBS 1% BSA 10 mM MgCl2
and resuspended in PBS 1% BSA 10 mM MgCl2. Sample
fluorescence was read on a multimode microplate reader
for both Alexa Fluor 488 (anti-kappa) and Alexa Fluor
647 (DeNAno).
DNA modeling
mFold (The RNA Institute, College of Arts and Sciences,
SUNY Albany, NY, USA) was used for DNA model-
ing. DNA conditions used were: 4◦C conditions with 0.15
M Na+ and 0.01 M Mg2+ ionic conditions. Representa-
tive structures are shown when the output provided more
than one structure. Motif analysis was performed with the
MEME suite program (12).
RESULTS
Streptavidin-binding DeNAno
The well-characterized protein streptavidin was the first tar-
get chosen to determine if DeNAno particles could be se-
lected against a defined protein. A library of DeNAno par-
ticles was made as described in ‘Materials and Methods’
section and used in a selection on streptavidin-coated mag-
netic beads as outlined in Figure 1A. All oligonucleotide
sequences are listed in Supplementary Table S1 (MJ library
and primers). Following five rounds of selection, a popula-
tion of streptavidin-binding particles emerged, as indicated
by a >10-fold increase in fluorescently-labeled DeNAno
bound to streptavidin, from library to round five (Figure
1B). The 100-bp core oligo of sixteen round five-selected
DeNAno was sequenced. Four sequences were identified,
including one dominant clone, SA-D8, which represented
11/16 sequences obtained (Table 1). All clones bound to
streptavidin-coated beads, but not BSA-coated beads (Fig-
ure 1C). A random clone from the same library was used
as a negative control (G10neg) and showed no binding to
the beads. This same clone was incubated with a biotiny-
lated complementary oligo and used as a positive control
(G10bio). SA-D8 was also tested on streptavidin-coated
sepharose and PMMA beads to confirm binding speci-
ficity for streptavidin (Supplementary Figure S1A and B).
Sequence analysis was performed on these clones using
MEME suite program (12) and a motif was identified, AC-
GACGCA (Supplementary Figure S2A andB). DNAmod-
eling put this motif in part of a stem-loop structure for each
of the four clones (Supplementary Figure S2C). Interest-
ingly, similar binding motifs or low-homology motifs with
conserved nucleotides in the binding region have been re-
ported for streptavidin-binding aptamers from four other
laboratories (13–16). In these cases, the motif was impor-
tant for aptamer binding to streptavidin, and this binding
was inhibited by biotin.
The dominant DeNAno clone, SA-D8, was imaged us-
ing atomic force microscopy (AFM; Figure 2A) and TEM
(Figure 2B and C, and Supplementary Figure S3A). For
TEM, both ‘standard’ (the size of particle used throughout
the paper) and ‘small’ (used in Figure 2D) particles were
made. In all cases, discreet ‘balls’ of DNA were observed,
with a diameter of 100–250 nm (AFM), 75 nm (standard
DeNAno/TEM) or, 58 nm (small DeNAno/TEM), similar
in size to previous reports using nanoparticle tracking sys-
tem (Nanosight) (2). The disparity between TEMandAFM
size of standardDeNAno is most likely due to the compact-
ness of the imaged DeNAno, which is partly determined by
the amount of salt present in the sample and the preparation
method. An image of the ‘standard’ size library particles is
also included in Supplementary Figure S3B.
To assess binding capability, standard and small size De-
NAno were made by varying dNTP concentration in the
RCA reaction. The DeNAno tested were SA-D7, SA-D8,
G10neg, G10bio and V10control. V10control is a DeNAno
from a different library which was made in two different
sizes andmixed with the experimental particles for use as an
internal control. DeNAno bound to streptavidin beads and
total samples were analyzed by qPCR. A standard was run
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Figure 1. Selection of streptavidin-binding DeNAno. (A) Schematic of selection process. (B) Staining of streptavidin selection rounds 1–5. Probe-only,
library and positive control (biotinylated library) are also shown. (C) Staining of four selected streptavidin clones on streptavidin beads and BSA-coated
beads. Negative control clone (G10neg) and biotinylated positive control clone (G10bio) also shown.
Figure 2. Imaging of DeNAno and staining different size DeNAno. (A) Atomic forcemicrograph (AFM) of driedDeNAno SA-D8 on poly-L-lysine-coated
mica. Scale = 400 nm. (B) SA-D8 DeNAno roughly 75 nm in diameter as observed by transmission electron microscopy (TEM) using negative staining.
Scale = 100 nm. (C) TEM of small SA-D8 DeNAno roughly 58 nm in diameter. Scale = 100 nm. (D) Binding of streptavidin DeNAno of different sizes
made by alteration of dNTP concentration. DeNAno particles were made with 3 nmol dNTPs for 30 m at 30◦C (the standard conditions), or 93.8 pmol
dNTPs for 30 m at 30◦C. A control DeNAno from a different library was also made for both of these conditions and used as an internal control in the
staining and subsequent PCR. The ratio of the bound particles (streptavidin DeNAno:control DeNano) to total particles (streptavidin DeNAno:control
DeNAno) is graphed.
for each library––10-fold dilutions of a plasmid containing
the 100-bp DeNAno template. The ratio of the bound par-
ticles to total particles is shown in Figure 2D. At the stan-
dard particle size, all particles except G10neg bound to the
streptavidin beads, as indicated by their high bound:total
ratios. When the particle size was reduced, SA-D7 bind-
ing dramatically dropped off and was only slightly above
background (G10neg); SA-D8 and G10bio binding were
not greatly affected. This result may indicate that SA-D7
DeNAno is more dependent on total avidity than SA-D8
to bind its target. This suggests DeNAno are not simply
aptamers made into concatemers by RCA, which has been
previously demonstrated (3).
Surface plasmon resonance (SPR) and kinetic exclusion
assays (KCA) were unsuccessfully attempted to obtain a Kd
value for theDeNAnoparticles. In the case of SPR, no read-
ing was obtained, perhaps due to the spacing of the target
(streptavidin) on the chip, as it is likely that one DeNAno
binds multiple streptavidin. For KCA, binding to the strep-
tavidin PMMA beads was observed, however, the binding
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Figure 3. Dissociation of streptavidin-binding DeNAno over time.
Streptavidin-coated magnetic beads were stained with DeNAno particles.
The stained beads were then incubated in 10ml buffer for 35 days. Aliquots
were taken every week of the total sample (supernatant plus beads) and
supernatant only (beads were removed by magnet). PCR was done on
all samples/timepoints and percentage release is graphed (DeNAno in
supernatant/DeNAno in total * 100%).
could not be inhibited by free streptavidin and thus no value
could be obtained (data not shown). Instead, a dissocia-
tion time course was performed, using SA-D7, SA-D8 and
G10bio (Figure 3). DeNAno were incubated with strepta-
vidin beads, washed extensively and the DeNAno-coated
beads were resuspended in 10ml buffer. Samples were taken
weekly through day 35 and either analyzed directly or the
beadswere pelleted and the supernatant analyzed.DeNAno
binding to the streptavidin beads was remarkably durable,
with only ∼12% of total particles found in the supernatant
at day 35. This dissociation was only 9.9-fold (SA-D7) and
11-fold (SA-D8) above that of G10bio.
SA-D8 was tested for binding in the presence of competi-
tor oligo (Supplementary Figure S4). An excess of 100-bp
oligo with the same sequence as the SA-D8 DeNAno was
pre-incubated with streptavidin beads, followed by addition
of fluorescently-labeled DeNAno. No inhibition of SA-D8
binding was observed in the presence of SA-D8 competitor
oligo or irrelevant oligo, suggesting the DeNAno requires
multiple copies of the oligo sequence to bind or that the
avidity of the DeNAno is sufficiently greater than the affin-
ity of the individual oligos for streptavidin.
To further define the properties of DeNAno, the effect
of buffer composition on the binding capacity of the par-
ticles was evaluated. SA-D7, SA-D8, G10neg and G10bio
were selected for testing. The following conditions were as-
sessed: MgCl2 concentration, NaCl concentration, physio-
logic buffers and biologic buffers. It is known that cations
such as magnesium and sodium can reduce repulsion along
the negatively charged backbone of the ssDNA, resulting
in particles with more flexibility and shorter effective length
(17). Thus, alteration of these cation concentrations may af-
fect the structure of the particle, and thus ability to bind.
For MgCl2 concentration, binding was observed in ≥5 mM
MgCl2, with no adverse effects up to 40 mMMgCl2; no ef-
fect on binding was observed for 0–300 mMNaCl (Supple-
mentary Figure S5A and B). Binding was observed in all
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Figure 4. Competitive titration and competitive release of streptavidin-binding DeNAno with biotin/biotin derivatives or streptavidin. (A) Schematic of
competitive titration using biotin/biotin derivatives. (B) Free biotin (top), desthiobiotin (middle) and 2-iminobiotin (bottom) competition titrations were
done by pre-incubating streptavidin beadswith one of the biotin/biotin derivatives (or buffer for the baseline), then addingDeNAnoparticles. (C) Schematic
of competitive release using biotin/biotin derivatives. (D) Biotin (top), desthiobiotin (middle) and 2-iminobiotin (bottom) competitive release assays were
done by staining streptavidin beads with DeNAno particles, then adding biotin/biotin derivative (or buffer for baseline). (E) Schematic of streptavidin
competitive titration. (F) Free streptavidin competition titration of SA-D7 and SA-D8 clones and G10bio positive control. Fluorescently-labeled DeNAno
particles were pre-incubated with varying concentrations of free streptavidin, then streptavidin beads were added.
physiologic buffers tested, with some variability in intensity
(Supplementary Table S2 and Supplementary Figure S5C).
High levels of fluorescence were observed in MES, HEPES,
bicine, CAPSO, carbonate, sodium phosphate, PBS and
TBS, and lower fluorescence signal (but still above G10neg
signal) was observed in PIPES, citrate and water. Finally,
particle binding was tested in 1.1, 3.3, 10 and 30% urine,
FBS and human serum (Supplementary Figure S5D). SA-
D8 bound streptavidin beads in all conditions except 30%
urine, while SA-D7 did not bind in 10% urine or 30% of
any biologic buffer. Overall, these results indicate the De-
NAno particles bind in a variety of buffers and conditions,
and perhaps unsurprising, are suited for the conditions they
were selected in––namely 10mMMgCl2, 150mMNaCl and
tris or sodium phosphate buffer. Additionally, the particles’
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ability to bind in biologic buffers demonstrates potential for
diagnostic or in vivo use.
As streptavidin-specific aptamers have previously been
shown to be displaced from their target by biotin, SA-
D7, SA-D8, G10neg and G10bio DeNAno were tested for
binding to streptavidin in the presence of biotin and bi-
otin derivatives in two assay formats (competitive titration
and competitive release, Figure 4A–D). In the competitive
titration assay, different concentrations of biotin, desthio-
biotin or 2-iminobiotin (pH 7.5) were pre-incubated with
streptavidin beads, then fluorescently-labeledDeNAno par-
ticles were added, further incubated, washed and fluores-
cence measured on a multimode microplate reader (Fig-
ure 4A and B). All particles were inhibited by high doses
of biotin or biotin derivative. In the case of biotin and
desthiobiotin, this inhibition occurred slightly below the es-
timated stoichiometric dose of 1:1 biotin:streptavidin sites
(53.3 nM biotin). For 2-iminobiotin, whose Kd decreases
with pH,∼10 000-fold excess was required to completely in-
hibit DeNAno binding. These same clones were also tested
in a competitive release experiment, in which streptavidin
beads were pre-incubated with fluorescently-labeled De-
NAno particles, followed by addition of biotin, desthiobi-
otin, or 2-iminobiotin, further incubated, washed and fluo-
rescence measured on a multimode microplate reader (Fig-
ure 4C and D). G10bio particle showed no decrease in fluo-
rescence, due to the exceptionally slow dissociation kinet-
ics of biotin-streptavidin. SA-D7 and SA-D8 showed de-
creased fluorescence for all biotin derivatives at the same
concentrations observed for the competitive titration exper-
iment. Thus, these streptavidin-binding DeNAno particles
are not only inhibited, but also removed by ligand. Ligand
displacement of DeNAno essentially transforms a protein
binding event into a DNA signal––a feature that could have
use as a high throughput ligand-receptor sensor.
Next, the competitive titration assay was used to directly
test whether free streptavidin could inhibit DeNAno bind-
ing (Figure 4E and F). Free streptavidin was pre-incubated
with fluorescently-labeled DeNAno, followed by addition
of streptavidin beads. G10bio performed as expected, ex-
hibiting a sharp decrease in fluorescence at the estimated
1:1 stoichiometric dose. SA-D7 and SA-D8, however, re-
quired 100–1000-fold excess streptavidin to induce a de-
crease in signal. Thus, the DeNAno particles’ behavior ap-
pears contrary––they are removed/inhibited by free ligand
(biotin and derivatives), yet their binding is not inhibited
by excess target (streptavidin). In fact, they seem to bind
preferentially to aggregated streptavidin (bead) versus free
streptavidin. DeNAno particles are therefore unique affin-
ity reagents that bind in the presence of high concentrations
of free target and may be particularly useful in assays lim-
ited by the ‘high-dose hook effect’. This effect is observed
most often in lateral flow assays (LFA) or other assays that
do not employ an intermediate wash step. When there is an
overabundance of target in the assay, the detection and/or
capture antibodies are limiting, leading to target that is only
bound to one antibody and not both (leading to a false neg-
ative) (18–20).
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Figure 5. Antibody-specific DeNAno. (A) Staining of dominant clones from rituximab (3Rit1) and bevacizumab (Bev1) selections on specific monoclonal-,
irrelevant monoclonal- and human polyclonal IgG antibody-coated beads. (B) Competitive titration with rituximab-specific (Rit pept) or irrelevant peptide
(irr pept) was done by pre-incubating peptide with rituximab-coated polystyrene beads, followed by incubation with fluorescently-labeled3Rit1 DeNAno.
(C) Competitive release with peptide was done by pre-incubating rituximab-coated polystyrene beads with 3Rit1 DeNAno, followed by incubation with Rit
pept, irr pept or buffer. Total sample and sample released into the supernatant were measured by qPCR and percentage released is graphed. (D) Schematic
of high-dose hook effect experiment for DeNAno in high-dose conditions and anti-kappa in high-dose and low-dose conditions. (E) Protein G was pre-
incubated for 1 h with different concentrations of rituximab or bevacizumab. Alexa Fluor647-labeled 3Rit1 DeNAno, Bev1 DeNAno or Lib-neg DeNAno
(left y axis), or Alexa Fluor488-labeled anti-kappa human light chain antibody (right y axis) were then added and incubated for an additional 2 h, then
washed and measured for fluorescence. For anti-kappa light chain samples only: rituximab and bevacizumab samples <1-fold free antibody were diluted
with mouse IgG2b  to equal 1-fold total antibody. This was done to bind all free protein G sites before addition of anti-kappa antibody so it would not
bind non-specifically.
Rituximab- and bevacizumab-binding DeNAno
Phage display has previously identified peptides that bind
specifically to monoclonal antibodies (11,21,22). The De-
NAno selection technique was applied to monoclonal
antibody-coated beads to determine if DeNAno specific
for monoclonal antibodies could be identified with simi-
lar properties to the streptavidin-binding DeNAno. After
four rounds, a binding population emerged for both se-
lections and one dominant clone was identified for each
(Supplementary Figure S6 and Table 2). The binding of
these clones was tested on specific and irrelevant mono-
clonal antibody-coated beads, as well as polyclonal human
IgG-coated beads (Figure 5A). 3Rit1 (rituximab-specific)
bound with >10-fold signal above control beads and Bev1
(bevacizumab-specific) bound with >30-fold signal.
Next, competitive titration and competitive release ex-
periments were performed with 3Rit1 DeNAno and a
previously-identified rituximab-specific mimetope peptide
(11) to determine if these DeNAno could also be used as
a ligand-receptor sensor. For the competitive titration, 0–
50 g/ml rituximab peptide or irrelevant peptide was pre-
incubated with rituximab-coated beads, followed by addi-
tion of fluorescently-labeled 3Rit1 DeNAno. 3Rit1 exhib-
ited a decrease in fluorescence only in the presence of 50
g/ml rituximab peptide (Figure 5B). In the competitive re-
lease experiment, 3Rit1 was pre-incubated with rituximab-
coated beads, followed by addition of 50 g/ml rituximab
peptide, irrelevant peptide or buffer. Total samples and su-
pernatant samples were compared via qPCR to determine
the percentage of DeNAno displaced from the bead (Fig-
ure 5C). Like the streptavidin-specific DeNAno, rituximab-
specific 3Rit1 was also released from the target by ligand.
This finding further supports the potential application of
DeNAno particles as ligand-receptor sensors, whereby a
protein-binding event can be reverse-translated into an am-
plifiable DNA signature.
Finally, 3Rit1 and Bev1 DeNAno and anti-kappa light
chain antibody were tested in a protein G sandwich assay
to assess DeNAno’s ability to overcome the high-dose hook
effect (Figure 5D and E). Wash steps were not used until
the end of the protocol, as in LFA. First, varying concen-
trations of rituximab or bevacizumab were pre-incubated
with protein G magnetic beads. For anti-kappa antibody
samples, mouse IgG was mixed with rituximab and beva-
cizumab samples that were less than bead-saturating to fill
the open protein G binding sites and prevent non-specific
antibody binding. Fluorescently-labeled DeNAno particles
or anti-kappa antibody were then added (with no washing)
and further incubated. After this incubation, beads were
washed via magnetic pulldown and analyzed by multimode
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microplate reader. The results are graphed as fold-excess
free antibody versus fluorescence (Figure 5E). Even in con-
ditions of 100-fold excess free antibody, both DeNAno par-
ticles were able to bind their target with no decrease in sig-
nal (left y axis). Also, no background staining was observed
on irrelevant beads and no binding was observed with non-
selected particles (lib-neg). As expected, anti-kappa bind-
ing was susceptible to the high-dose hook effect, peaking
at 0.1-fold (bevacizumab) or 1-fold (rituximab) and steadily
decreasing in fluorescence intensity with increasing free an-
tibody (right y axis). These data parallel the results obtained
in the free streptavidin competition and confirm that De-
NAno preferentially bind aggregated target over free target.
DISCUSSION
DeNAno particles have previously been selected against cel-
lular targets (1,2). However, characterization of these par-
ticles has been limited by the anonymity of the target. Se-
lection of the particles against a well-characterized protein,
streptavidin, has allowed for analysis of binding in a variety
of conditions, binding competition, particle size required
for binding and particle half-life, and has also identified
unique features of DeNAno. Two key unique features were
observed: (i) DeNAno are displaced from their target by the
corresponding ligand and this event can be quantitated by
fluorescence or qPCR, (or in the future, high-throughput
sequencing) and (ii) DeNAno display a preference for bind-
ing to aggregated versus free target and can thus overcome
the high-dose hook effect in the presence of 100–1000-fold
excess free target (Figure 6A and B).
DeNAno particle displacement from a target by its lig-
and transforms a protein binding event into a DNA signal,
a powerful feature that has potential applicability in high-
throughput, highly multiplexed protein or biomarker detec-
tion assays. There is increasing need for these types of assays
as tissue banks becomemore expansive, patterns of markers
instead of single markers become validated and pharmaco-
logic responses to therapy become more utilized. Current
methods, such as mass spectrometry, protein microarrays
and bead-based detection assays (e.g., Luminex) exhibit sev-
eral disadvantages, namely a requirement for specialized
and expensive detection equipment, a limit on the degree
of multiplexing and/or limited utility for high-throughput
screening. A detection assay based on displacement of De-
NAno particles would leverage the power and commoditi-
zation of sequencing to enable massively parallel analyses
that can be inexpensively outsourced to any academic or
commercial facility.
In addition to remedying the high-dose hook effect in
LFA, DeNAno particles that preferentially bind aggregated
target in the presence of free target have potential in bio-
logic detection and targeting. DeNAno particles could be
used to identify clusters or aggregates of protein in the pres-
ence of large amounts of free (non-aggregated) protein, such
as cell-surface antibody in serum-rich environment, fibrin
in clots in the presence of free fibrinogen and Alzheimer’s-
associated amyloid plaques in the presence of amyloid .
The DeNAno likely bind and rapidly release free (individ-
ual) targets because only one or a few binding regions are
engaged on the particle. It is only when the target is aggre-
sample
Detect by fluorescence, PCR, or sequencing
DeNAno
mAb-coated bead
mAb ligands
concentration-dependant displacement of DeNAno by ligand
A
B
DeNAno
aggregated target
free target
Figure 6. Key features of DeNAno. (A) DeNAno bind bead-aggregated
target, but are displaced by ligand, transforming a protein-binding event
into a DNA signature. (B) DeNAno bind aggregated target in the presence
of a large excess of free target.
gated that a ‘velcro-like’ interaction can take place–that is,
multiple binding sites on the particle binding to multiple
targets. This may begin as a ‘toehold’ of only a few bind-
ings, with the proximity leading to more DeNAno binding
site-aggregated target engagements. Thus, when one bind-
ing site on the DeNAno detaches, multiple others maintain
the DeNAno-aggregated target interaction. Furthermore,
due to this proximity, rebinding of unbound DeNAno sites
may occur more rapidly than DeNAno/free target.
In summary,DeNAno particles hold potential promise as
unique and powerful affinity reagents in assays that require
massively parallel multiplex detection of binding events, as-
says which lack an intermediate wash step (e.g. LFA) and
other systems where aggregated target must be detected in
the presence or absence of free target (e.g. blood clots).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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